Skip to content
← Full study record

NCT00366106 · MORE INFO

Limitations, agreements, and source contact

Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma · Source last updated 2012-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
A copy of the disclosure must be given to Millennium for review at least 30 days before it is submitted for publication or disclosure. If a Development is contained in the disclosure, Research Organization and/or Principal Investigator defer publication or disclosure for 90 days from the time Millennium notifies that it wants to file a patent application on the Development provided such notice was provided by Millennium within 30 days of the copy first provided to Millennium.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was closed to enrollment when it became clear that enrollment was too slow to complete the planned enrollment target of 45 patients within the time frame allowed. Response rate was unable to be assessed due to missingness of required data.
point Of Contact
email
mwalker@acorncro.com
organization
Accelerated Community Oncology Research Network, Inc.
phone
901-435-5570
title
Vice President of Scientific Affairs
Complete source fields
certain Agreement
other Details
A copy of the disclosure must be given to Millennium for review at least 30 days before it is submitted for publication or disclosure. If a Development is contained in the disclosure, Research Organization and/or Principal Investigator defer publication or disclosure for 90 days from the time Millennium notifies that it wants to file a patent application on the Development provided such notice was provided by Millennium within 30 days of the copy first provided to Millennium.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The study was closed to enrollment when it became clear that enrollment was too slow to complete the planned enrollment target of 45 patients within the time frame allowed. Response rate was unable to be assessed due to missingness of required data.
point Of Contact
email
mwalker@acorncro.com
organization
Accelerated Community Oncology Research Network, Inc.
phone
901-435-5570
title
Vice President of Scientific Affairs

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice